Jove
Visualize
Contact Us

Related Experiment Videos

Akt-regulated pathways in prostate cancer.

Pradip K Majumder1, William R Sellers

  • 1Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA.

Oncogene
|November 17, 2005
PubMed
Summary

Genetic inactivation of the PTEN gene is common in aggressive prostate cancer. This leads to activation of key signaling pathways, offering new therapeutic targets like mTOR and PI3K inhibitors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Context-dependent synthetic lethality - an emerging precision therapeutic approach.

Nature reviews. Cancer·2026
Same author

Systematic cysteine scanning identifies a druggable pocket in oncogenic KRAS.

Cell chemical biology·2026
Same author

RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors.

Molecular cancer research : MCR·2025
Same author

CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer.

Cancer research·2025
Same author

Targeting KIT With Antibody-Drug Conjugates in Chromophobe Renal Cell Carcinoma.

Clinical genitourinary cancer·2025
Same author

Prospects for understanding and exploiting the consequences of hyperactivation lethality.

Trends in cancer·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Prostate cancer is a leading cause of cancer mortality.
  • Understanding the molecular drivers of aggressive prostate cancer is crucial.
  • Genetic alterations in PTEN are implicated in cancer progression.

Purpose of the Study:

  • To investigate the role of PTEN genetic inactivation in prostate cancer.
  • To identify therapeutic opportunities arising from PTEN alterations.
  • To explore the activation of downstream signaling pathways.

Main Methods:

  • Analysis of genetic alterations in PTEN.
  • Investigation of phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway activation.
  • Review of emerging therapeutic strategies targeting these pathways.

Main Results:

  • Genetic inactivation of PTEN (gene deletion or mutation) is frequent in metastatic prostate cancer.
  • PTEN loss results in the activation of the PI3K/AKT/mTOR signaling cascade.
  • This pathway activation presents a significant therapeutic vulnerability.

Conclusions:

  • PTEN inactivation is a key event in aggressive prostate cancer.
  • Targeting the PI3K/AKT/mTOR pathway offers a promising therapeutic strategy.
  • Emerging inhibitors (mTOR, HSP90, PI3K) hold potential for treating PTEN-altered prostate cancer.

Related Experiment Videos